In silico molecular docking was conducted to assess the binding affinity of major bioactive constituents to NAFLD‐associated targets, including PPAR‐α, PPAR‐γ, AMPK, and SREBP‐1c. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.